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Abstract:
Objective: To increase awareness of unusual inflammatory and responses including severe insulin resistance associated with the use of targeted immunotherapies such as brentuximab.
Methods: We report the case of a man without a previous diagnosis of diabetes, who developed diabetic ketoacidosis complicated by severe insulin resistance (unresponsive to >600 units intravenous insulin/hour) after receiving brentuximab for Hodgkin's lymphoma.
Results: Autoantibodies to the insulin receptor were not detected in the patient's serum, thus excluding a diagnosis of type B insulin resistance.
Conclusions: We hypothesize that brentuximab administration led to a rare reaction leading to systemic cytokine release with extreme insulin resistance in our patient.
Abbreviations:
HIV= Human Immunodeficiency Virus; DKA = diabetic ketoacidosis; IV = intravenous; GAD-65 = glutamic acid decarboxylase 65; IL-6 = interleukin 6; IL-10 = interleukin 10; IL-2 = interleukin 2; FDA = Food and Drug Administration; TNF-R = Tumor necrosis factor receptor.
Introduction:
Use of targeted immunotherapies including brentuximab have changed the landscape in cancer therapeutics but have also unveiled new drug toxicities from inducing inflammation and autoimmunity. We report a case of a patient who, after receiving his first dose of brentuximab, was admitted with new diabetic ketoacidosis and severe insulin resistance.
Case:
A 54-year-old Caucasian man with human immunodeficiency virus (HIV) (CD4 count 199, viral load undetectable) on antiretroviral therapy and Hodgkin's lymphoma, without history of diabetes nor hyperglycemia, received his first dose of brentuximab for treatment of lymphoma. One week later, the patient presented to the emergency room with fatigue, polydipsia, and polyuria. Initial tests showed the glucose was 25 mmol/L (450 mg/dL) (normal: Autopsy revealed a normal-appearing pancreas, a known malignant abdominal mass, and no infectious sources or major emboli as explanations of death. Samples of the patient's serum, which were collected pre-and post-plasmapheresis, were analyzed postmortem. Both samples were tested for the presence of anti-insulin receptor autoantibodies by immunoprecipitation as previously described (1, 2), and the results were negative.
Conclusion:
This is the first report to our knowledge of the development of extreme insulin resistance in a patient without a previous diagnosis of diabetes nor hyperglycemia after brentuximab infusion. Brentuximab is an anti-CD30 monoclonal antibody drug conjugate approved in 2011 for use in Hodgkin's lymphoma. Brentuximab targets cells expressing CD30, leading to subsequent internalization of the anti-tubulin agent (monomethyl auristatin E) and cell death.
CD30 is expressed on Hodgkin's cells but also is found on T-regulatory cells and on activated Tcells producing Th2-type cytokines.
One previous case of severe cytokine release has been reported with brentuximab treatment (3). The reported case had a similar presentation to our patient with vasopressordependent shock, oliguria, and increase in inflammatory cytokines. Unlike our patient, the reported case patient had a reaction to brentuximab within 60 minutes of the infusion, survived, and did not develop severe insulin resistance. There may be milder cases that have been unreported. In fact, a search of the FDA Adverse Events Reporting System (4) (data as of August 20, 2019) shows 70 reported reactions of "hyperglycemia" or "blood glucose increase", 10 reports of "DKA", and 7 cases of "cytokine release syndrome" or "cytokine storm".
Initially, we also suspected the presence of an insulin antibody or type B insulin resistance due to the massive amount of insulin required to treat the DKA, though specific antibodies to insulin and the insulin receptor were not identified in this patient. However, given the unusual presentation in this case, the patient may have developed antibodies that were not detected through traditional assays. We speculate that brentuximab administration led to a rare reaction leading to systemic cytokine release with extreme insulin resistance in our patient. We that included antibodies to the insulin receptor and a cytokine cascade, which ultimately resulted in the patient's death.
Our proposed mechanism for brentuximab contributing to severe cytokine release and extreme insulin resistance remains speculative. CD30 is part of the TNF-R superfamily expressed on T-regulatory cells. It plays a role in protection from allograft rejection (5) and in autoimmune diseases such as rheumatoid arthritis (6) . Depletion of CD30 can lead to compromise of negative selection in the thymus and increased T-cell autoreactivity; blockade of the CD30 pathway reduces protection by T-regulatory cells from proinflammatory cytokine accumulation and T-cell apoptosis (7) . Interestingly, signaling through CD30 has also been shown in murine models as one pathway to protect against the development of autoimmune diabetes (8) .
Other rare disorders have been described with brentuximab which may be related to immunomodulation or severe inflammation, including progressive multifocal leukoencephalopathy (9-11) and toxic epidermal necrolysis (12) . This may point to a pattern in which brentuximab, in select patients, is related to a decrease in immune surveillance and "unleashing" of autoimmunity. We hope this case report increases clinician awareness and vigilance for unusual inflammatory and autoimmune manifestations, especially as use of targeted immunotherapies for cancers increase. More case reports and clinical trials will be needed to uncover the genetic, immune, and cancer profiles that may increase susceptibility to rare inflammatory or immune-related events from targeted immunotherapies.
